Sponsor content

Patient-friendly treatments for neuronal ceroid lipofuscinoses

Polaryx Therapeutics is working to bring patient-friendly treatments to people with ultra-rare genetic disorders known as neuronal ceroid lipofuscinoses (NCLs), the most common of which is Batten disease.

Go to the profile of Polaryx Therapeutics
Jun 06, 2017
0
0
Page of
Go to the profile of Polaryx Therapeutics

Polaryx Therapeutics

Polaryx Therapeutics, Inc is a biotech company devoted to the development of therapeutic interventions for Neuronal Ceroid Lipofuscinosis (NCL), a group of rare genetic lysosomal storage disorders in children. NCL is also known as Batten disease. Among the subtypes of NCL, we are focusing on the development of patient-friendly oral medications for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL or CLN2). Children with CLN2 have progressive deterioration of their mental and motor functions, visual failure, and seizures leading to premature death. The disease has no cure, and thus has a high unmet medical need.

No comments yet.